{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:19:34Z","timestamp":1790518774125,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL128288"],"award-info":[{"award-number":["R01HL128288"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL141781"],"award-info":[{"award-number":["R01HL141781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1212391"],"award-info":[{"award-number":["OPP1212391"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ymthe.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T01:14:50Z","timestamp":1599354890000},"page":"822-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["In\u00a0Vivo HSC Gene Therapy Using a Bi-modular HDAd5\/35++ Vector Cures Sickle Cell Disease in a Mouse Model"],"prefix":"10.1016","volume":"29","author":[{"given":"Chang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aphrodite","family":"Georgakopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sucheol","family":"Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Yannaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Lieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2020.09.001_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V21.3.261.261","article-title":"Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore","volume":"21","author":"Conley","year":"1963","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib2","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.V46.5.683.683","article-title":"A new form of hereditary persistence of fetal hemoglobin in blacks and its association with sickle cell trait","volume":"46","author":"Stamatoyannopoulos","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/01.HS9.0000564780.30358.eb","article-title":"Updated Results From The Hgb-206 Study In Patients With Severe Sickle Cell Disease Treated Under A Revised Protocol With Lentiglobin Gene Therapy Using Plerixafor-Mobilised Haematopoietic Stem Cells","volume":"3","author":"Kanter","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.ymthe.2020.09.001_bib4","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1038\/s41467-019-12456-3","article-title":"Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders","volume":"10","author":"Uchida","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.001_bib5","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bbmt.2014.07.016","article-title":"Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification","volume":"20","author":"Anurathapan","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2020.09.001_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1054\/blre.2002.0192","article-title":"The cure of thalassemia by bone marrow transplantation","volume":"16","author":"Lucarelli","year":"2002","journal-title":"Blood Rev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/asheducation.V2003.1.372.0010372","article-title":"Hematopoietic cell transplantation for benign hematological disorders and solid tumors","volume":"2003","author":"Storb","year":"2003","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2020.09.001_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/blood-2016-04-711580","article-title":"In\u00a0vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors","volume":"128","author":"Richter","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib9","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/mtna.2016.44","article-title":"A High-Capacity Adenoviral Hybrid Vector System Utilizing the Hyperactive Sleeping Beauty Transposase SB100X for Enhanced Integration","volume":"5","author":"Boehme","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2020.09.001_bib10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/ng.343","article-title":"Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates","volume":"41","author":"M\u00e1t\u00e9s","year":"2009","journal-title":"Nat. Genet."},{"issue":"4S1","key":"10.1016\/j.ymthe.2020.09.001_bib11","first-page":"241","article-title":"In\u00a0vivo HSC gene therapy for hemoglobinopathies: a proof of concept evaluation in rhesus macaques [Abstract\u00a0546]","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"issue":"Suppl.","key":"10.1016\/j.ymthe.2020.09.001_bib12","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2019.37.15_suppl.2062","article-title":"A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ\/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit","volume":"37","author":"Sloan","year":"2019","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib13","doi-asserted-by":"crossref","first-page":"133ra57","DOI":"10.1126\/scitranslmed.3003425","article-title":"Extended survival of glioblastoma patients after chemoprotective HSC gene therapy","volume":"4","author":"Adair","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2020.09.001_bib14","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1172\/JCI76739","article-title":"Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients","volume":"124","author":"Adair","year":"2014","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.09.001_bib15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1172\/JCI122836","article-title":"In\u00a0vivo hematopoietic stem cell gene therapy ameliorates murine thalassemia intermedia","volume":"129","author":"Wang","year":"2019","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.09.001_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtm.2018.02.004","article-title":"Integrating HDAd5\/35++ Vectors as a New Platform for HSC Gene Therapy of Hemoglobinopathies","volume":"9","author":"Li","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1749-6632.1998.tb10460.x","article-title":"Molecular basis of hereditary persistence of fetal hemoglobin","volume":"850","author":"Forget","year":"1998","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.ymthe.2020.09.001_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/asheducation-2011.1.459","article-title":"Targeted therapeutic strategies for fetal hemoglobin induction","volume":"2011","author":"Sankaran","year":"2011","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.ymthe.2020.09.001_bib19","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/ncomms8085","article-title":"Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin","volume":"6","author":"Wienert","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2020.09.001_bib20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.ymthe.2020.09.001_bib21","first-page":"284","article-title":"CRISPR\/Cas9 genome editing to treat sickle cell disease and beta-thalassemia: Re-creating genetic variants to upregulate fetal hemoglobin appear well-tolerated, effective and durable","volume":"130","author":"Lin","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.001_bib23","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.001_bib24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","article-title":"Therapeutic base editing of human hematopoietic stem cells","volume":"26","author":"Zeng","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2020.09.001_bib25","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2018-03-838540","article-title":"Reactivation of \u03b3-globin in adult \u03b2-YAC mice after ex\u00a0vivo and in\u00a0vivo hematopoietic stem cell genome editing","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2006-02-004812","article-title":"Correction of sickle cell disease by homologous recombination in embryonic stem cells","volume":"108","author":"Wu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1126\/science.278.5339.873","article-title":"Knockout-transgenic mouse model of sickle cell disease","volume":"278","author":"Ryan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.001_bib29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1172\/JCI200318782","article-title":"Methylguanine methyltransferase-mediated in\u00a0vivo selection and chemoprotection of allogeneic stem cells in a large-animal model","volume":"112","author":"Neff","year":"2003","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2020.09.001_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.omtm.2017.11.004","article-title":"A Combined In\u00a0Vivo HSC Transduction\/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice","volume":"8","author":"Wang","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib28","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.1038\/mtm.2014.57","article-title":"Efficient genome editing in hematopoietic stem cells with helper-dependent Ad5\/35 vectors expressing site-specific endonucleases under microRNA regulation","volume":"1","author":"Saydaminova","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib31","doi-asserted-by":"crossref","first-page":"e59890","DOI":"10.1371\/journal.pone.0059890","article-title":"Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells","volume":"8","author":"Kurita","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2020.09.001_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in\u00a0situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.001_bib33","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.ymthe.2019.08.006","article-title":"Targeted Integration and High-Level Transgene Expression in AAVS1 Transgenic Mice after In\u00a0Vivo HSC Transduction with HDAd5\/35++ Vectors","volume":"27","author":"Li","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.001_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.omtm.2018.04.008","article-title":"HDAd5\/35++ Adenovirus Vector Expressing Anti-CRISPR Peptides Decreases CRISPR\/Cas9 Toxicity in Human Hematopoietic Stem Cells","volume":"9","author":"Li","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib35","doi-asserted-by":"crossref","first-page":"139538","DOI":"10.1172\/jci.insight.139538","article-title":"Curative in\u00a0vivo hematopoietic stem cell gene therapy of murine thalassemia using large regulatory elements","volume":"5","author":"Wang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2020.09.001_bib36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"P\u00e1szty","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.001_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","article-title":"Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors","volume":"569","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2020.09.001_bib38","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41587-019-0236-6","article-title":"CRISPR DNA base editors with reduced RNA off-target and self-editing activities","volume":"37","author":"Gr\u00fcnewald","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib39","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tibtech.2018.06.005","article-title":"The Human Genome Editing Race: Loosening Regulatory Standards for Commercial Advantage?","volume":"37","author":"Cathomen","year":"2019","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib41","doi-asserted-by":"crossref","first-page":"10547","DOI":"10.1073\/pnas.0711666105","article-title":"In\u00a0vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia","volume":"105","author":"Miccio","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2020.09.001_bib42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2013-09-528067","article-title":"Fetal hemoglobin in sickle cell anemia: a glass half full?","volume":"123","author":"Steinberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib43","series-title":"The Molecular Basis of Blood Diseases","first-page":"107","article-title":"Hemoglobin switching","author":"Stamatoyannopolous","year":"1994"},{"key":"10.1016\/j.ymthe.2020.09.001_bib44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0955-0674(98)80012-4","article-title":"Locus control regions, chromatin activation and transcription","volume":"10","author":"Fraser","year":"1998","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib45","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1101\/gad.13.19.2465","article-title":"Looping versus linking: toward a model for long-distance gene activation","volume":"13","author":"Bulger","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2020.09.001_bib46","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2020.09.001_bib47","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1089\/hum.2005.16.664","article-title":"Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons","volume":"16","author":"Ni","year":"2005","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.001_bib48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib49","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1002\/1873-3468.13696","article-title":"Innate immunity to adenovirus: lessons from mice","volume":"593","author":"Atasheva","year":"2019","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2020.09.001_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/10430340460732445","article-title":"Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates","volume":"15","author":"Brunetti-Pierri","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2020.09.001_bib51","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2020.09.001_bib52","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/mt.2008.297","article-title":"Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy","volume":"17","author":"Seregin","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.001_bib53","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1182\/blood-2005-06-2335","article-title":"Survival of the fittest: in\u00a0vivo selection and stem cell gene therapy","volume":"107","author":"Neff","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib54","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41375-018-0277-8","article-title":"Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR\/Cas9-deletion of CD33 exon 2","volume":"33","author":"Humbert","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl. 1","key":"10.1016\/j.ymthe.2020.09.001_bib55","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood-2019-122770","article-title":"Truncated erythropoietin receptors confer an in\u00a0vivo selective advantage in gene-modified erythroid cells expressing fetal hemoglobin due to bcl11a interference","volume":"134","author":"Uchida","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2020.09.001_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/0008-5472.CAN-19-1044","article-title":"Prophylactic In\u00a0Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models","volume":"80","author":"Li","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2020.09.001_bib57","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ymthe.2003.08.014","article-title":"Improved system for helper-dependent adenoviral vector production","volume":"8","author":"Palmer","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2020.09.001_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/978-1-59745-060-7_8","article-title":"Ex\u00a0vivo generation of human red blood cells: a new advance in stem cell engineering","volume":"482","author":"Douay","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib59","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt1319","article-title":"An improved zinc-finger nuclease architecture for highly specific genome editing","volume":"25","author":"Miller","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib60","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ymthe.2020.09.001_bib61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ymthe.2020.09.001_bib62","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2249.2001.01458.x","article-title":"Membrane cofactor protein (MCP; CD46) expression in transgenic mice","volume":"124","author":"Kemper","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymthe.2020.09.001_bib63","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1749-6632.1998.tb10459.x","article-title":"beta-YAC transgenic mice for studying LCR function","volume":"850","author":"Peterson","year":"1998","journal-title":"Ann. N Y Acad. Sci."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620304585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001620304585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:02:06Z","timestamp":1761501726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001620304585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":63,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1525001620304585"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.001","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0Vivo HSC Gene Therapy Using a Bi-modular HDAd5\/35++ Vector Cures Sickle Cell Disease in a Mouse Model","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.01.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}